Skip to contentP
Precision Biosciences Inc
P
DTILPrecision Biosciences Inc Q3 2025 · 10-Q
Revenue$13.00K$13.00K−97.7% vs Q3 2024 Net Income-$21.77M-$21.77MN/M vs Q3 2024 EPS Diluted-$1.84-$1.84N/M vs Q3 2024 Operating Income-$20,667,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Precision Biosciences Inc · CIK 1357874 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$15,270,000N/M Margins · derivedOperating margin-158976.9%−155283.3 pt vs Q3 2024
Net margin-167476.9%−164625.4 pt vs Q3 2024
ended Sep 30, 2025 · filed Nov 3, 2025 · 34 d after period end